AGENUS INC Finite-Lived Intangible Assets, Accumulated Amortization
AGENUS INC (AGEN) had Finite-Lived Intangible Assets, Accumulated Amortization of $17.48 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $17.48M.
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $17.40M.
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $17.32M.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $17.24M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization | Finite-Lived Intangible Assets, Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $17.48M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $17.40M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $17.32M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $17.24M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $17.16M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $17.07M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $16.99M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $18.06M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $18.03M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $17.80M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $17.69M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $17.44M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $17.12M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $16.70M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $16.15M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $15.59M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $15.20M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $14.41M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $13.96M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $13.34M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $12.81M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $12.18M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $11.84M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $11.14M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $10.50M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $9.92M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $9.43M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $8.88M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $8.45M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $7.92M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $7.47M 10-K · filed 2020-03-16 | $7.47M 10-K · filed 2019-03-18 |
| 2018-09-30 | $7.00M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $6.48M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $6.06M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $5.46M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $4.95M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $4.42M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $3.78M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $3.19M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $2.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.13M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.58M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $987.39K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $873.67K 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $769.38K 10-Q · filed 2015-08-03 | |
| 2015-03-31 | $609.85K 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $462.25K 10-K · filed 2016-03-15 | |
| 2014-09-30 | $343.41K 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $219.89K 10-Q · filed 2014-08-01 | |
| 2014-03-31 | -$74.00K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $0.00 10-Q · filed 2014-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |